Baidu
map

Cancer Res.:陷窝蛋白-1调节大肠癌有氧糖酵解

2012-06-18 bo 生物谷

6月15日,Cancer Research杂志在线报道了在大肠癌中,陷窝蛋白-1通过刺激HMGA1介导的GLUT3转录,增加有氧糖酵解。 陷窝蛋白-1(CAV1)在多种人类恶性肿瘤中作为生长抑制因子,但在许多晚期癌症中其表达升高,提示其在肿瘤进展中的致癌开关作用。为理解CAV1增长促进作用的分子基础,研究者分析了其在肿瘤生长中的表达状态和在分化中的作用,以及它对大肠癌肿瘤的生长和糖代谢的影响。在

6月15日,Cancer Research杂志在线报道了在大肠癌中,陷窝蛋白-1通过刺激HMGA1介导的GLUT3转录,增加有氧糖酵解。

陷窝蛋白-1(CAV1)在多种人类恶性肿瘤中作为生长抑制因子,但在许多晚期癌症中其表达升高,提示其在肿瘤进展中的致癌开关作用。为理解CAV1增长促进作用的分子基础,研究者分析了其在肿瘤生长中的表达状态和在分化中的作用,以及它对大肠癌肿瘤的生长和糖代谢的影响。在很大一部分原发肿瘤和细胞系中,可检测到CAV1的异常升高。这与启动子CpG位点的低甲基化紧密相关。

升高CAV1的消耗,导致AMPK活化和随后的p53依赖的G1细胞周期阻滞和细胞自噬。这表明升高CAV1可能促进ATP生成。此外,CAV1的消耗可下调葡萄糖的摄取,乳酸堆积和细胞内ATP水平。这提示,CAV1增强有氧糖酵解。相应的,研究结果表明CAV1通过一个GLUT3启动子内的HMGA1结合位点,刺激GLUT3的转录。

研究还发现,HMGA1与GLUT3启动子相互作用并活化它,而CAV1通过加强HMGA1的核定位来增加其活力。 HMGA1的异位表达增加葡萄糖的摄取,而其表达下调导致AMPK激活。此外,共转染CAV1和HMGA1可诱导GLUT3强烈表达。GLUT3过度表达主要表现在高水平表达CAV1和HMGA1的肿瘤中。总之,这些数据显示,升高的CAV1通过HMGA1介导的GLUT3转录上调葡萄糖的摄取和ATP的生产。这表明,CAV1提高有氧糖酵解可能导致肿瘤细胞的生长优势。

 

doi:10.1016/j.cell.2011.10.017
PMC:

PMID:

Caveolin-1 Increases Aerobic Glycolysis in Colorectal Cancers by Stimulating HMGA1-Mediated GLUT3 Transcription

Sung-Gil Chi1,*, Tae-Kyu Ha1, Nam-Gu Her1, Min-Goo Lee1, Byung-Kyu Ryu1, Jin-Hee Lee1, Jikhyon Han1, Seong-In Jeong1, Min-Ju Kang1, Nam-Hoon Kim2, and Hyo-Jong Kim3

Caveolin-1 (CAV1) acts as a growth suppressor in various human malignancies but its expression is elevated in many advanced cancers, suggesting the oncogenic switch of its role during tumor progression. To understand the molecular basis for the growth-promoting function of CAV1, we characterized its expression status, differential roles for tumor growth and effect on glucose metabolism in colorectal cancers. Abnormal elevation of CAV1 was detected in a substantial fraction of primary tumors and cell lines and tightly correlated with promoter CpG sites hypomethylation. Depletion of elevated CAV1 led to AMPK activation followed by a p53-dependent G1 cell cycle arrest and autophagy, suggesting that elevated CAV1 may contribute to ATP generation. Furthermore, CAV1 depletion down-regulated glucose uptake, lactate accumulation and intracellular ATP level, supporting that aerobic glycolysis is enhanced by CAV1. Consistently, CAV1 was shown to stimulate GLUT3 transcription via a HMGA1-binding site within the GLUT3 promoter. HMGA1 was found to interact with and activate the GLUT3 promoter and CAV1 increased the HMGA1 activity by enhancing its nuclear localization. Ectopic expression of HMGA1 increased glucose uptake while its knockdown caused AMPK activation. In addition, GLUT3 expression was strongly induced by co-transfection of CAV1 and HMGA1 and its overexpression was observed predominantly in tumors harboring high levels of CAV1 and HMGA1. Together, these data show that elevated CAV1 up-regulates glucose uptake and ATP production through HMGA1-mediated GLUT3 transcription, suggesting that CAV1 may render tumor cells growth advantages by enhancing aerobic glycolysis.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=168540, encodeId=a263168540ab, content=又是糖酵解啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=79401629895, createdName=Wuhuayan, createdTime=Sat Jan 07 11:25:15 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818734, encodeId=66a21818e3400, content=<a href='/topic/show?id=49af9841ef6' target=_blank style='color:#2F92EE;'>#陷窝蛋白-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98417, encryptionId=49af9841ef6, topicName=陷窝蛋白-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Sat Feb 23 16:59:00 CST 2013, time=2013-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793217, encodeId=39931e9321792, content=<a href='/topic/show?id=3c7315338cb' target=_blank style='color:#2F92EE;'>#Res.:#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15338, encryptionId=3c7315338cb, topicName=Res.:)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Tue Aug 07 00:59:00 CST 2012, time=2012-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275763, encodeId=451312e576394, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Wed Jun 20 09:59:00 CST 2012, time=2012-06-20, status=1, ipAttribution=)]
    2017-01-07 Wuhuayan

    又是糖酵解啊

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=168540, encodeId=a263168540ab, content=又是糖酵解啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=79401629895, createdName=Wuhuayan, createdTime=Sat Jan 07 11:25:15 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818734, encodeId=66a21818e3400, content=<a href='/topic/show?id=49af9841ef6' target=_blank style='color:#2F92EE;'>#陷窝蛋白-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98417, encryptionId=49af9841ef6, topicName=陷窝蛋白-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Sat Feb 23 16:59:00 CST 2013, time=2013-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793217, encodeId=39931e9321792, content=<a href='/topic/show?id=3c7315338cb' target=_blank style='color:#2F92EE;'>#Res.:#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15338, encryptionId=3c7315338cb, topicName=Res.:)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Tue Aug 07 00:59:00 CST 2012, time=2012-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275763, encodeId=451312e576394, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Wed Jun 20 09:59:00 CST 2012, time=2012-06-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=168540, encodeId=a263168540ab, content=又是糖酵解啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=79401629895, createdName=Wuhuayan, createdTime=Sat Jan 07 11:25:15 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818734, encodeId=66a21818e3400, content=<a href='/topic/show?id=49af9841ef6' target=_blank style='color:#2F92EE;'>#陷窝蛋白-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98417, encryptionId=49af9841ef6, topicName=陷窝蛋白-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Sat Feb 23 16:59:00 CST 2013, time=2013-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793217, encodeId=39931e9321792, content=<a href='/topic/show?id=3c7315338cb' target=_blank style='color:#2F92EE;'>#Res.:#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15338, encryptionId=3c7315338cb, topicName=Res.:)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Tue Aug 07 00:59:00 CST 2012, time=2012-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275763, encodeId=451312e576394, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Wed Jun 20 09:59:00 CST 2012, time=2012-06-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=168540, encodeId=a263168540ab, content=又是糖酵解啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=79401629895, createdName=Wuhuayan, createdTime=Sat Jan 07 11:25:15 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818734, encodeId=66a21818e3400, content=<a href='/topic/show?id=49af9841ef6' target=_blank style='color:#2F92EE;'>#陷窝蛋白-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98417, encryptionId=49af9841ef6, topicName=陷窝蛋白-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Sat Feb 23 16:59:00 CST 2013, time=2013-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793217, encodeId=39931e9321792, content=<a href='/topic/show?id=3c7315338cb' target=_blank style='color:#2F92EE;'>#Res.:#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15338, encryptionId=3c7315338cb, topicName=Res.:)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Tue Aug 07 00:59:00 CST 2012, time=2012-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275763, encodeId=451312e576394, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Wed Jun 20 09:59:00 CST 2012, time=2012-06-20, status=1, ipAttribution=)]

相关资讯

Cancer Immunol Immun:研究人员积极开发新的抗癌疫苗

近日,Moffitt癌症中心的研究人员给小鼠体内注射一种人工合成疫苗后,发现它能有效杀死人类乳头状瘤病毒导致的癌症。 这项研究结果发表在最近一期??的Cancer Immunology, Immunotherapy杂志上。 人类乳头状瘤病毒(Human papillomavirus,HPV)是一种嗜上皮性病毒,在人和动物中分布广泛,有高度的特异性,长期以来,已知HPV可引起人类良性的肿瘤和疣,

Cancer Cell:LKB1基因失活驱动黑色素瘤转移

为什么某些癌症会迅速蔓延到其他器官,而某些人却不发生转移?Norman Sharpless博士,领导的UNC研究团队近日确定了一个关键基因开关,该基因决定了一种致命的皮肤癌--黑色素瘤是否会发生转移扩散。 黑色素瘤(melanoma)又称恶性黑色素瘤,是一种能产生黑色素的高度恶性肿瘤。大多见于30岁以上成年人,发生于皮肤、粘膜和内脏器官。黑色素瘤的预后多数较差,晚期可有淋巴道及血液转移。黑色素瘤

Cancer Cell:弥散性大B细胞淋巴瘤协同性化疗新进展

6月12日,Cancer Cell杂志报道了弥散性大B细胞淋巴瘤化学协同治疗的最新进展。 癌基因突变的知识,可催生靶向性杀死癌细胞而避免正常细胞受害的治疗手段。来那度胺在弥散性大B细胞淋巴瘤(DLBCL)的活化B细胞样(ABC)亚型中是一种活性药物。由于ABC DLBCL细胞中存在MYD88癌基因,来那度胺可通过促进干扰素β (IFNβ)的产生来杀死这些癌细胞。 来那度胺以cereblon依赖

Cancer Res.:DNA应激和p53影响肿瘤细胞TOLL样受体表达

6月6日,Cancer Research在线报道,肿瘤细胞中DNA应激和p53状态可差异性影响TOLL样受体固有免疫家族的表达。 转录因子p53调节包括TOLL样受体(TLR)在内的固有免疫相关基因的表达。这提示p53也调节人类免疫反应。TLR家族构成识别病原相关的分子模式(PAMPs)的细胞膜糖蛋白,介导固有免疫反应。TLR激动剂已被用于肿瘤治疗的佐剂。 研究证实,阿霉素、5氟尿嘧啶、紫外线

Cancer Cell:去泛素化酶调节肝炎、纤维化和癌变

6月12日,Cancer Cell杂志报道了去泛素化酶,圆柱瘤病(CYLD)肿瘤抑制因子的失活可引发肝细胞的凋亡、炎症、纤维化和癌症。圆柱瘤病(CYLD)肿瘤抑制因子通过去泛素化上游因子,抑制NFκB和有丝分裂原活化蛋白激酶(MAPK)活化途径。 本研究显示,肝特异性阻断CYLD通过自发的或慢性激活TGF-β活化激酶1(TAK1)和c-Jun N末端激酶(JNK)触发了肝门静脉周边区域肝细胞的死

Cancer Res.:VEGF在肿瘤中的非促血管生成活性

据6月15日,Cancer Research杂志在线报道,血管内皮生长因子在肿瘤恶性进展过程中所发挥的不仅是促血管生成功能。 血管内皮生长因子/血管通透性因子(VEGF / VPF或VEGF-A)是肿瘤血管生成的关键驱动力,也是治疗恶性肿瘤的重要治疗靶点。然而,很少有研究工作涉及VEGF不依赖于其促血管生成活性的那部分功能。 该研究表明,由肿瘤细胞产生的血管内皮生长因子以自分泌方式,通过与血管

Baidu
map
Baidu
map
Baidu
map